Phase 3 enrollment of 417 patients for the landmark MODEL trial of a novel peptide intradiscal injection for low back pain is now completed. Study sponsor, Spine BioPharma, Inc., made this announcement at the recently concluded 2024 North American Spine Society annual meeting.
The post Phase 3 Enrollment Done for 1st Intradiscal Back Pain Injection first appeared on Orthopedics This Week.